PCA3 score of 20 could improve prostate cancer detection: Results obtained on 734 Italian individuals

Clinica Chimica Acta

Volumn 429, Issue , 2014, Pages 46-50

  Capoluongo, Ettore ^a   Zambon, Carlo Federico ^b   Basso, Daniela ^b   Boccia, Stefania ^c   Rocchetti, Sandro ^a   Leoncini, Emanuele ^c   Palumbo, Sara ^a   Padoan, Andrea ^b   Albino, Giuseppe ^a   Todaro, Angelo ^b   Prayer Galetti, Tommaso ^b   Zattoni, Filiberto ^b   Zuppi, Cecilia ^a   Plebani, Mario ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

PCa; PCA3 score; Progensa

Indexed keywords

MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER RISK; CANCER SCREENING; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL RECTAL EXAMINATION; ECHOGRAPHY; FALSE POSITIVE RESULT; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PATIENT MONITORING; PCA3 SCORE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REFERENCE VALUE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

PCA; PCA3 SCORE; PROGENSA;

ANTIGENS, NEOPLASM; HUMANS; ITALY; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; REFERENCE VALUES; RISK; ROC CURVE; URINALYSIS;

EID: 84890020831     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.10.022     Document Type: Article

References (25)

1. Garnick M.B. Prostate cancer: screening, diagnosis, and management. Ann Intern Med 1993, 118:804-818.
2. Dall'Era M.A., Cooperberg M.R., Chan J.M., et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 2008, 112:1650-1659.
3. Schroder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360:11320-11328.
4. Lacetera V., Galosi A.B., Cantoro U., et al. Transrectal ultrasound (TRUS) and TRUS-biopsy accuracy in potential candidates for PRIAS active surveillance protocol. Arch Ital Urol Androl 2012, 84:272-275.
5. Heidenreich A., Bellmunt J., Bolla M., et al. European Association of Urology. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011, 59:61-71.
6. Barbera M., Pepe P., Paola Q., Aragona F. PCA3 score accuracy in diagnosing prostate cancer at repeat biopsy: our experience in 177 patients. Arch Ital Urol Androl 2012, 84:227-229.
7. Deras I.L., Aubin S.M., Blase A., et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008, 179:1587-1592.
8. Goode R.R., Marshall S.J., Duff M., Chevli E., Chevli K.K. Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients. Prostate 2013, 73:48-53.
9. de la Taille A., Irani J., Graefen M., et al. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J Urol 2011, 185:2119-2125.
10. Auprich M., Haese A., Walz J., et al. External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome. Eur Urol 2010, 58:727-732.
11. Aubin S.M., Reid J., Sarno M.J., et al. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol 2010, 184:1947-1952.
12. Salagierski M., Mulders P., Schalken J.A. Predicting prostate biopsy outcome using a PCA3-based nomogram in a Polish cohort. Anticancer Res 2013, 33:553-557.
13. Roobol M.J. Contemporary role of prostate cancer gene 3 in the management of prostate cancer. Curr Opin Urol 2011, 21:225-229.
14. Roobol M.J., Schröder F.H., van Leeuwen P., et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 2010, 58:475-481.
15. Bradley L.A., Palomaki G.E., Gutman S., Samson D., Aronson N. Comparative effectiveness review: prostate cancer antigen 3 (PCA3) testing for the diagnosis and management of prostate cancer. J Urol 2013, [Epub ahead of print]. 10.1016/j.juro.2013.02.005.
16. Pepe P., Fraggetta F., Galia A., Skonieczny G., Aragona F. PCA3 score and prostate cancer diagnosis at repeated saturation biopsy. Which cut-off: 20 or 35?. Int Braz J Urol 2012, 38:489-495.
17. Gittelman M.C., Hertzman B., Bailen J., et al. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. J Urol 2013, [Epub ahead of print]. 10.1016/j.juro.2013.02.018.
18. Pepe P., Aragona F. PCA3 score vs PSA free/total accuracy in prostate cancer diagnosis at repeat saturation biopsy. Anticancer Res 2011, 31:4445-4449.
19. Augustin H., Mayrhofer K., Pummer K., Mannweiler S. Relationship between prostate cancer gene 3 (PCA3) and characteristics of tumor aggressiveness. Prostate 2013, 73:203-210.
20. Leyten G.H., Wierenga E.A., Sedelaar J.P., et al. Value of PCA3 to predict biopsy outcome and its potential role in selecting patients for multiparametric MRI. Int J Mol Sci 2013, 14:11347-11355.
21. Auprich M., Chun F.K., Ward J.F., et al. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol 2011, 59:96-105.
22. Nakanishi H., Groskopf J., Fritsche H.A., et al. Pca3 molecular urine assay correlates with prostate cancer tumor volume: Implication in selecting candidates for active surveillance. J Urol 2008, 179:1804-1809. [discussion 1809-1810].
23. Hessels D., van Gils M.P., van Hooij O., Jannink S.A., Witjes J.A., Verhaegh G.W., et al. Predictive value of pca3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate 2010, 70:10-16.
24. Ploussard G., Durand X., Xylinas E., et al. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol 2011, 59:422-429.
25. Ferro M., Bruzzese D., Perdonà S., et al. Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. Clin Chim Acta 2012, 413:1274-1278.